Efficacy of solifenacin on irritable bowel syndrome with diarrhea

Open-label prospective pilot trial

Yasushi Fukushima, Hidekazu Suzuki, Juntaro Matsuzaki, Arihiro Kiyosue, Toshifumi Hibi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background/Aims: Solifenacin, a muscarinic type 3 receptor antagonist, is used to treat overactive bladder in adults. The aim of this study is to examine the efficacy of solifenacin on the symptomatic relief of diarrhea predominant irritable bowel syndrome (IBS-D). Methods: A total of 20 patients with IBS-D were enrolled. After a 2-week observation period, all participants received solifenacin for 6 weeks. Subsequently, the administration of solifenacin was discontinued and ramosetron, a serotonin 3 receptor antagonist, was administered for 4 weeks. Overall improvement, the IBS-symptom severity scale (IBS-SSS), and frequency of defecation were assessed. Results: Six weeks after initiation of solifenacin treatment and 4 weeks after initiation of ramosetron treatment, overall improvement was observed in 19 out of 20 (95%) and 17 out of 20 (85%) participants, respectively. At 2 weeks after initiation of solifenacin, overall improvement was observed in 16 out of 20 participants (80%). Total IBS-SSS scores at 2 and 6 weeks after the administration of solifenacin, and at 4 weeks after administration of ramosetron, were significantly lower than those at week 0. Compared to before administration, the participants' quality of life and frequency of defecation were significantly lower in all participants at 2 and 6 weeks after the administration of solifenacin and at 4 weeks after administration of ramosetron. Conclusions: The efficacy of solifenacin in the treatment of IBS with diarrhea was not inferior to that of ramosetron. Further placebo-controlled parallel studies are needed.

Original languageEnglish
Pages (from-to)317-323
Number of pages7
JournalJournal of Neurogastroenterology and Motility
Volume18
Issue number3
DOIs
Publication statusPublished - 2012

Fingerprint

Irritable Bowel Syndrome
Diarrhea
Defecation
Solifenacin Succinate
Receptors, Serotonin, 5-HT3
Overactive Urinary Bladder
Serotonin Antagonists
Muscarinic Receptors
Therapeutics
Placebos
Quality of Life
Observation
ramosetron

Keywords

  • Diarrhea
  • Overactive
  • Ramosetron
  • Solifenacin succinate
  • Urinary bladder

ASJC Scopus subject areas

  • Gastroenterology
  • Clinical Neurology

Cite this

Efficacy of solifenacin on irritable bowel syndrome with diarrhea : Open-label prospective pilot trial. / Fukushima, Yasushi; Suzuki, Hidekazu; Matsuzaki, Juntaro; Kiyosue, Arihiro; Hibi, Toshifumi.

In: Journal of Neurogastroenterology and Motility, Vol. 18, No. 3, 2012, p. 317-323.

Research output: Contribution to journalArticle

Fukushima, Yasushi ; Suzuki, Hidekazu ; Matsuzaki, Juntaro ; Kiyosue, Arihiro ; Hibi, Toshifumi. / Efficacy of solifenacin on irritable bowel syndrome with diarrhea : Open-label prospective pilot trial. In: Journal of Neurogastroenterology and Motility. 2012 ; Vol. 18, No. 3. pp. 317-323.
@article{1a9347a5dcb740c29d05d6f78b3bc0f1,
title = "Efficacy of solifenacin on irritable bowel syndrome with diarrhea: Open-label prospective pilot trial",
abstract = "Background/Aims: Solifenacin, a muscarinic type 3 receptor antagonist, is used to treat overactive bladder in adults. The aim of this study is to examine the efficacy of solifenacin on the symptomatic relief of diarrhea predominant irritable bowel syndrome (IBS-D). Methods: A total of 20 patients with IBS-D were enrolled. After a 2-week observation period, all participants received solifenacin for 6 weeks. Subsequently, the administration of solifenacin was discontinued and ramosetron, a serotonin 3 receptor antagonist, was administered for 4 weeks. Overall improvement, the IBS-symptom severity scale (IBS-SSS), and frequency of defecation were assessed. Results: Six weeks after initiation of solifenacin treatment and 4 weeks after initiation of ramosetron treatment, overall improvement was observed in 19 out of 20 (95{\%}) and 17 out of 20 (85{\%}) participants, respectively. At 2 weeks after initiation of solifenacin, overall improvement was observed in 16 out of 20 participants (80{\%}). Total IBS-SSS scores at 2 and 6 weeks after the administration of solifenacin, and at 4 weeks after administration of ramosetron, were significantly lower than those at week 0. Compared to before administration, the participants' quality of life and frequency of defecation were significantly lower in all participants at 2 and 6 weeks after the administration of solifenacin and at 4 weeks after administration of ramosetron. Conclusions: The efficacy of solifenacin in the treatment of IBS with diarrhea was not inferior to that of ramosetron. Further placebo-controlled parallel studies are needed.",
keywords = "Diarrhea, Overactive, Ramosetron, Solifenacin succinate, Urinary bladder",
author = "Yasushi Fukushima and Hidekazu Suzuki and Juntaro Matsuzaki and Arihiro Kiyosue and Toshifumi Hibi",
year = "2012",
doi = "10.5056/jnm.2012.18.3.317",
language = "English",
volume = "18",
pages = "317--323",
journal = "Journal of Neurogastroenterology and Motility",
issn = "2093-0879",
publisher = "Korean Society of Neurogastroenterology and Motility",
number = "3",

}

TY - JOUR

T1 - Efficacy of solifenacin on irritable bowel syndrome with diarrhea

T2 - Open-label prospective pilot trial

AU - Fukushima, Yasushi

AU - Suzuki, Hidekazu

AU - Matsuzaki, Juntaro

AU - Kiyosue, Arihiro

AU - Hibi, Toshifumi

PY - 2012

Y1 - 2012

N2 - Background/Aims: Solifenacin, a muscarinic type 3 receptor antagonist, is used to treat overactive bladder in adults. The aim of this study is to examine the efficacy of solifenacin on the symptomatic relief of diarrhea predominant irritable bowel syndrome (IBS-D). Methods: A total of 20 patients with IBS-D were enrolled. After a 2-week observation period, all participants received solifenacin for 6 weeks. Subsequently, the administration of solifenacin was discontinued and ramosetron, a serotonin 3 receptor antagonist, was administered for 4 weeks. Overall improvement, the IBS-symptom severity scale (IBS-SSS), and frequency of defecation were assessed. Results: Six weeks after initiation of solifenacin treatment and 4 weeks after initiation of ramosetron treatment, overall improvement was observed in 19 out of 20 (95%) and 17 out of 20 (85%) participants, respectively. At 2 weeks after initiation of solifenacin, overall improvement was observed in 16 out of 20 participants (80%). Total IBS-SSS scores at 2 and 6 weeks after the administration of solifenacin, and at 4 weeks after administration of ramosetron, were significantly lower than those at week 0. Compared to before administration, the participants' quality of life and frequency of defecation were significantly lower in all participants at 2 and 6 weeks after the administration of solifenacin and at 4 weeks after administration of ramosetron. Conclusions: The efficacy of solifenacin in the treatment of IBS with diarrhea was not inferior to that of ramosetron. Further placebo-controlled parallel studies are needed.

AB - Background/Aims: Solifenacin, a muscarinic type 3 receptor antagonist, is used to treat overactive bladder in adults. The aim of this study is to examine the efficacy of solifenacin on the symptomatic relief of diarrhea predominant irritable bowel syndrome (IBS-D). Methods: A total of 20 patients with IBS-D were enrolled. After a 2-week observation period, all participants received solifenacin for 6 weeks. Subsequently, the administration of solifenacin was discontinued and ramosetron, a serotonin 3 receptor antagonist, was administered for 4 weeks. Overall improvement, the IBS-symptom severity scale (IBS-SSS), and frequency of defecation were assessed. Results: Six weeks after initiation of solifenacin treatment and 4 weeks after initiation of ramosetron treatment, overall improvement was observed in 19 out of 20 (95%) and 17 out of 20 (85%) participants, respectively. At 2 weeks after initiation of solifenacin, overall improvement was observed in 16 out of 20 participants (80%). Total IBS-SSS scores at 2 and 6 weeks after the administration of solifenacin, and at 4 weeks after administration of ramosetron, were significantly lower than those at week 0. Compared to before administration, the participants' quality of life and frequency of defecation were significantly lower in all participants at 2 and 6 weeks after the administration of solifenacin and at 4 weeks after administration of ramosetron. Conclusions: The efficacy of solifenacin in the treatment of IBS with diarrhea was not inferior to that of ramosetron. Further placebo-controlled parallel studies are needed.

KW - Diarrhea

KW - Overactive

KW - Ramosetron

KW - Solifenacin succinate

KW - Urinary bladder

UR - http://www.scopus.com/inward/record.url?scp=84872872762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872872762&partnerID=8YFLogxK

U2 - 10.5056/jnm.2012.18.3.317

DO - 10.5056/jnm.2012.18.3.317

M3 - Article

VL - 18

SP - 317

EP - 323

JO - Journal of Neurogastroenterology and Motility

JF - Journal of Neurogastroenterology and Motility

SN - 2093-0879

IS - 3

ER -